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Tissue-engineered vascular grafts (TEVGs†) hold great promise for the improvement of out-
comes in pediatric patients with congenital cardiac anomalies. Currently used synthetic
grafts have several limitations, including thrombogenicity, increased risk of infection, and
lack of growth potential. The first pilot clinical trial of TEVGs demonstrated the feasibility of
this new technology and revealed an excellent safety profile. However, long-term follow-up
from this trial revealed the primary graft-related complication to be stenosis, affecting 16
percent of grafts within 7 years post-implantation. In order to determine the mechanism be-
hind TEVG stenosis and ultimately to create improved second generation TEVGs, our group
has returned to the bench to study vascular neotissue formation in a variety of large and
small animal models. The purpose of this report is to review the recent advances in the un-
derstanding of neotissue formation and vascular tissue engineering.
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thors.inTroDuCTion
Native vessels remain the gold standard
in revascularization procedures; however,
such autologous grafts are not always ob-
tainable secondary to limited availability or
concurrent disease. While synthetic grafts
such as expanded polytetrafluoroethylene
(Gortexﾮ, W.L. Gore & Associates, Newark,
DE)  and  polyethylene  terephthalate
(Dacronﾮ, Dupont, Wilmington, DE) have
been used in the past, they have an increased
risk of thrombosis and intimal hyperplasia
[1-3]. Moreover, the lack of growth potential
associated with synthetic grafts is particu-
larly limiting in the pediatric population,
where multiple operations and graft oversiz-
ing become necessary to ensure adequate
blood  flow.  Tissue-engineered  vascular
grafts (TEVGs) represent a potentially limit-
less supply of autologous grafts with the
added benefit of growth potential. In its most
basic form, vascular tissue engineering in-
volves  seeding  autologous  cells  onto  a
biodegradable tubular scaffold which serves
as a site of cell attachment and neotissue for-
mation. Once the graft is implanted, neotis-
sue begins to form while the biodegradable
scaffold slowly dissolves. The end result is a
neovascular conduit composed entirely of
the autologous tissue [4]. Multiple large an-
imal studies have demonstrated the feasibil-
ity of tissue engineering in the construction
of vascular grafts [5-8].
Tissue engineering has been described
as “an interdisciplinary field that applies the
principles of engineering and life sciences to-
ward the development of biological substi-
tutes that restore, maintain, or improve tissue
function or a whole organ” [4]. As the field
moves from the laboratory to the clinic, all
aspects of TEVG construction (scaffold ma-
terials, cells for seeding grafts, and seeding
techniques) will need to be re-evaluated to
ensure adequate safety and efficacy. Just as
importantly, clinical experience should dic-
tate laboratory investigation of the process of
neotissue formation in a concerted effort to
move beyond first generation TEVG and
onto  second  generation  TEVG  with  im-
proved hemodynamic functionality and in
vivo performance.
CliniCAl SignifiCAnCE
Even with the implementation of innova-
tive medical and surgical treatment modali-
ties, congenital heart disease (CHD) remains
the most common form of death in the new-
born  period  [9].  Estimates  of  the  current
birthrate indicate that approximately 1.35 mil-
lion infants worldwide are born with CHD
each year, representing a major global health
burden [10]. The development of a man-made
vascular conduit for use in pediatric patients
with cardiac anomalies holds particular prom-
ise for the advancement of the field.
Single ventricle anomalies are comprised
of a large and diverse group of structural ir-
regularities that result in a life-threatening
form of CHD characterized by chronic hy-
poxia and cyanosis. This classification in-
cludes diseases such as hypoplastic left heart
syndrome, double inlet left ventricle, and pul-
monary atresia. The unifying feature of each
condition is the mixing of the oxygenated sys-
temic circulation with the deoxygenated pul-
monary  circulation,  leading  to  volume
overload and heart failure with a mortality of
up to 70 percent during the first year of life if
left untreated [11]. Surgical reconstruction is
the preferred approach in the management of
single ventricle physiology. One of the more
commonly performed procedures is a series
of  staged  operations  termed  the  modified
Fontan  operation  with  extracardiac  total
cavopulmonary  connection  (EC  TCPC),
which allows the single ventricle to pump
oxygenated blood through the systemic circu-
lation. The EC TCPC procedure is designed
to directly connect the inferior vena cava
(IVC) to the pulmonary artery and is the most
commonly performed congenital heart opera-
tion in which a large caliber vascular graft is
implanted in a high-flow, low-pressure circu-
lation. While the operation has resulted in sub-
stantial improvements in long-term survival, it
is ultimately considered a palliative procedure
with  significant  morbidity  and  mortality
[12,13], and it is widely accepted that the ideal
conduit remains to be developed [14-16].
The most significant disadvantage of
synthetic conduits is their lack of growth po-
tential. Consequently, surgical repair may be
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where an adult-sized conduit can be used.
Performing the surgery prior to this point
risks the need for reoperation when the child
outgrows the original conduit, a precarious
proposition associated with increased risk of
complications and early post-operative mor-
tality rates of up to 5 percent [17]. Implant-
ing an oversized graft at an earlier age avoids
the complications of delayed treatment and
mitigates the possibility of the patient out-
growing the conduit, but this approach car-
ries an increased risk of complications [18].
Notably, a small subset of patients born with
CHD is amenable to primary repair without
the use of synthetic grafts. These patients are
not susceptible to the inherent risks of syn-
thetic  conduits,  and  their  outcomes  are
markedly improved [19]. Similarly, the use
of autografts — vascular conduits created
from an individual’s own tissue — results in
long-term patency rates that exceed 80 per-
cent [20]. This superior level of effectiveness
compared to synthetic grafts is mitigated by
limited availability, prompting the search for
a man-made graft that retains growth poten-
tial [17,19,20-22].
PiloT CliniCAl TriAl
Promising results in animal models led
to the initiation of a clinical pilot study in
Japan in 2001. The study was designed to
evaluate the safety and efficacy of TEVGs
for use in congenital heart surgery, specifi-
cally the EC TCPC operation in patients born
with single ventricle cardiac anomalies [23-
25].  TEVGs  were  created  by  seeding  a
biodegradable scaffold with autologous bone
marrow mononuclear cells (BM-MNCs) fol-
lowed by implantation in a cohort of 25 pa-
tients with congenital cardiac anomalies. The
initial follow-up period was set at 7 years and
included imaging studies such as contrast an-
giography and computed tomography (CT)
scanning in order to monitor the progression
of the implanted conduits. Each patient re-
ceived  between  3  and  6  months  of  an-
tiplatelet  and  anticoagulation  therapy
immediately following the procedure [6,25].
Early results from the study were encourag-
ing. The implanted conduits were universally
functional with no evidence of failure due to
thrombosis, stenosis, or obstruction of the
TEVGs. Additionally, angiography and CT
imaging revealed no evidence of aneurysm
formation or calcification. All grafts were
patent, and serial scans confirmed that the di-
ameter of the neovessel increased with time.
None of the patients required graft replace-
ment, and there was no mortality relating to
the implanted conduits. Antiplatelet and an-
ticoagulant medications were successfully
discontinued by all patients within 6 months
of the procedure, a marked contrast to the
lifetime  requirement  for  anticoagulation
when synthetic grafts are used. Additionally,
40 percent of patients did not require any
daily medication regimen. Late analysis of
the cohort again illustrated the absence of
graft-related mortality. However, 16 percent
of patients were revealed to have TEVG
stenosis at long-term follow-up. This finding
was frequently asymptomatic, and all pa-
tients were successfully treated with angio-
plasty or angioplasty and stenting [25].
Data from the initial clinical trial sug-
gest that TEVGs are indeed safe and effec-
tive for use in congenital heart surgery, but
the mechanisms of neovessel formation and
the processes leading to graft failure are in-
completely  understood.  Both  phenomena
must be investigated thoroughly if an im-
proved tissue-engineered vascular graft is to
become a reality. Additionally, the results of
the trial indicate that stenosis is the primary
means of graft-related failure. It is therefore
critical to gain a better understanding of the
mechanisms underlying TEVG stenosis in
order to identify the potential targets and
strategies that could prevent this complica-
tion. Ultimately, this would allow for the ra-
tional design of a second generation TEVG
with improved safety and efficacy.
TEVg ConSTruCTion
Scaffold Materials
Ideal scaffold material should possess
three characteristics, namely: (1) biodegrad-
ability,  (2)  non-immunogenicity,  and  (3)
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until neotissue formation takes place. Cur-
rent scaffold material can be broken up into
the subgroups of synthetic and biological.
Traditionally, synthetic materials have been
used, and scaffolds have been constructed
using woven polymers of polyglycolic acid
(PGA),  polylactic  acid  (PLA),  and  poly-
caprolactone (PCL). By combining and vary-
ing the concentrations of these polymers,
scaffolds can be generated to meet the com-
pliance specifications of the vascular envi-
ronment in which they are to be introduced
[26-28]. However, the degree to which the
compliance and biomechanical properties of
woven polymer scaffolds can be fine-tuned
is significantly less than that found in newer
construction techniques such as electrospin-
ning, in which an electrical field is used to
mold individual polymer fibers into a tubular
structure  upon  a  rotating  metal  rod  [29].
Other groups have focused on the use of bi-
ologic scaffolds, such as decellularized
human and porcine vessels and human
umbilical  vein.  These  materials  have
shown  a  high  degree  of  matching  of
compliance between graft and natural
vessels with little risk of immunogenic
response [30,31]. However, these meth-
ods have not yet been evaluated in clini-
cal trials, and their applicability in TEVG
constructions requires further study.
Cells for Seeding
Several  different  cell  types  have
been considered for use in TEVGs, in-
cluding endothelial cells, smooth mus-
cle cells, embryonic stem cells, induced
pluripotent stem cells, and BM-MNCs.
The ideal seeded cell should be easily
harvested,  require  a  short  incubation
time, and rapidly give rise to neotissue
formation. While the use of endothelial
cells and smooth muscles cells is entic-
ing due to their matching of natural ves-
sels, they require long in vitro incubation
times and thus increased risk of contam-
ination  [32,33].  Similarly,  embryonic
stem cells and induced pluripotent stem
cells have been considered due to their
potential  to  differentiate  into  the  en-
dothelial and smooth muscle cells of a ma-
ture vessel. However, these cells are not
always available, carry significant risk of
teratoma formation, and require more inves-
tigation before clinical use can be consid-
ered [34,35]. Conversely, BM-MNCs are
readily available via bone marrow aspiration
and require a relatively short, 2-hour scaf-
fold incubation time prior to implantation.
Our group has pioneered a novel process of
separating  BM-MNCs  from  the  aspirate
through the use of a specially designed filter
to separate cells of a particular size [36].
While the process of harvesting bone mar-
row mononuclear cells is not without some
risk to sterility and cell viability, its relative
speed and safety makes it the current fron-
trunner in the construction of TEVGs.
Seeding Techniques
Traditionally, scaffolds have been stati-
cally seeded through a process in which cells
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figure 1. Cell seeding of TEVg. a) Static
seeding. A cell suspension is pipetted onto the
outer surface and inner lumen of the scaffold. b)
Vacuum seeding. A cell suspension is forced
through a scaffold by internal pressure, thus
lodging the cells within the pores of the scaffold.
Remaining aspirate is collected in specimen
traps. (Adapted with permission from Villalona
(2010) [37] and Udelsman (2011) [38]).in media are pipetted onto the outer lumen
and into the inner lumen of the scaffold. The
cells are allowed several hours to attach to
the scaffold in vitro prior to implantation.
The drawbacks of this process have been
long recognized and include low seeding ef-
ficiency and the potential for intra- and inter-
operator variability. While many techniques
have  been  proposed,  including  dynamic,
magnetic, and electrostatic [37], none of
these  techniques  have  been  evaluated  in
clinical trials or fulfill the characteristics of
an ideal seeding system, which should be
rapid, automated, and standardized, while
maximizing cell viability and minimizing
risk of contamination. In an effort to reach
this ideal, our group utilizes a disposable
vacuum-seeding device in which negative
pressure is used to rapidly lodge cells in the
pores of a scaffold fastened to a perforated
tubular device connected to suction [38].
This vacuum-seeding device has been ap-
proved for use in a pilot clinical study and
achieves similar cell seeding viability and
efficiency as that seen in static seeding, but
with the advantage of automaticity and self-
containment (Figure 1).
BACk To BEnCH
Large Animal Studies
In  an  effort  to  better  understand  the
mechanisms behind TEVG stenosis, further
bench work studies are necessary in an effort
to  create  improved  second  generation
TEVGs. Using an ovine model, TEVGs have
been implanted as interpositional IVC grafts
in juvenile lambs and monitored with bi-
monthly  magnetic  resonance  angiography
over a 6-month time course. At the end of the
time  course,  all  grafts  were  patent  and
demonstrated an increase in volume propor-
tional to the native right pulmonary artery.
Explanted grafts at 6 months resembled na-
tive IVC in that they contained a similar wall
thickness with an inner monolayer of en-
dothelial cells surrounded by several layers
of smooth muscle cells in concentric layers.
These explanted grafts contained an extracel-
lular layer with collagen, elastin, and gly-
cosaminoglycan (GAG) contents comparable
to native IVC and a similar biomechanical
profile. Equally important, by 6 months, the
TEVG expressed Eph-B4, a marker of ve-
nous differentiation, suggesting that implan-
tation of TEVG in venous circulation leads to
formation of venous vascular neotissue [39].
Small Animal Studies
While this ovine model marked the first
time a TEVG demonstrated molecular evi-
dence of normal vascular development, a
mouse model was sought after to better char-
acterize the process of neotissue formation.
In this effort, sub-1mm tubular scaffolds
composed of similar materials used in the
pilot clinical trial were constructed. These
TEVGs  had  the  advantage  of  being  im-
plantable in immunodeficient SCID-beige
mice, enabling the use of TEVGs seeded
with human cells without the need for im-
munosuppression [40]. TEVGs seeded with
human BM-MNCs and implanted as IVC in-
terpositional grafts remained fully patent
and functional as venous conduits over a 6-
month time course. By 6 months, TEVGs
contained  a  mature  vascular  architecture
consisting of a confluent endothelial cell
lined intima and one to two layers of smooth
muscle cell media, while the original scaf-
fold material had degraded and was replaced
by a supportive adventitial layer of collagen
fibrils [41]. 
Extensive histological and immunohisto-
chemical characterization was performed to in-
vestigate the mechanism by which neotissue
formation within the TEVGs occurred. Al-
though it has been hypothesized that stem cells
within the seeded BM-MNC population dif-
ferentiate into the cells of the neotissue [42],
by 1 week after implantation, human BM-
MNCs were no longer detectable within the
TEVGs. Rather, it is hypothesized that these
seeded cells augment a host inflammatory
process via a paracrine mechanism through the
secretion of chemokines that recruit host cells
to the scaffold, ultimately leading to neovas-
cularization.  When  compared  to  unseeded
grafts, seeded grafts demonstrated a higher
concentration of macrophages during early
graft development. Notably, interleukin 1-beta
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tein-1 (MCP-1) were both found in abundant
quantity. Later experiments utilized alginate
microspheres containing MCP-1. Implanted
TEVGs with alginate microspheres incorpo-
rated into their walls developed and functioned
similar to human BM-MNC-seeded scaffolds
with an internal lumen containing organized
vascular neotissue [41] (Figure 2).
Regenerative Model of Neotissue 
Formation
The early abundance of host-derived in-
flammatory cells led to further investigations
on  the  proposed  role  for  mono-
cytes/macrophages in the process of
neovessel formation and the develop-
ment of graft stenosis. These studies
were performed by isolating mono-
cytes from the bone marrow of syn-
geneic C57BL/6 mice followed by
seeding onto the synthetic conduits
and implantation [43]. Histological
and immunohistochemical character-
ization revealed that this model suc-
cessfully recapitulated the results of
the human trial, with stenosis remain-
ing the primary graft-related compli-
cation. Early stenosis was observed in
80 percent of unseeded TEVGs, but
only 20 percent of seeded TEVGs,
with all stenoses occurring within 2
weeks of implantation. Additionally,
luminal diameter was significantly
higher in the seeded grafts. Quantifi-
cation of F4/80-positive macrophages
revealed significantly higher levels of
macrophage  infiltration  in  the  un-
seeded  grafts  compared  to  seeded
grafts. To determine whether these re-
lationships were causative or correla-
tive,  additional  TEVGs  were
implanted into CD11b-DTR trans-
genic mice treated with diphtheria
toxin to inhibit macrophage infiltra-
tion [44-46]. This conditional knock-
out  decreased  the  total  number  of
macrophages in the graft, increased
rates of patency, and increased lumi-
nal diameters. Macrophage inhibition
resulted in a decrease in neovessel
formation, with histological analysis revealing
the absence of both the endothelial and smooth
muscle layers, as well as reduced collagen dep-
osition. These experiments illustrate a direct
correlation between the degree of macrophage
infiltration and the formation of stenosis. The
data also highlight the well-recognized role of
macrophages in the processes of vascular re-
pair and remodeling.
This model of seeded cells augmenting
the host inflammatory response rather than
playing a direct role in the formation of neo-
tissue contrasts with the classic tissue engi-
neering theory of seeded cells “as building
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figure 2. TEVg development in mouse model.
Early pulse of cytokine (MCP-1) release from
seeded BM-MNC enhances monocyte recruitment to
the scaffold. Monocytes infiltrate the scaffold and di-
rect neotissue formation, leading to the recruitment
of smooth muscle cells from neighboring native ves-
sel wall. This process results in concentric layers of
smooth muscle cells embedded in an extracellular
matric with a monolayer of endothelial cells lining
the luminal surface. (Adapted with permission from
Roh (2010) [41]).block of neotissue” [28]. Rather, these stud-
ies suggest a regenerative medicine para-
digm, in which seeded cells merely promote
the host’s natural healing process. In line
with this paradigm are recent studies show-
ing that male-derived vessel segments im-
planted in female wild type mice previously
given green fluorescent protein bone mar-
row transplants give rise to neovessel tissue
originating from migration of the adjacent
vessel segment rather than from the seeded
cells or bone marrow [47].
This finding was further substantiated
by studies investigating the use of serial
magnetic resonance imaging (MRI) for non-
invasive monitoring of implanted vascular
grafts in a mouse model. The technique was
based upon the uptake of ultra-small super-
paramagnetic iron oxide (USPIO) particles
by monocyte derivatives which were then
seeded onto a biodegradable scaffold. MRI
of the grafts confirmed the presence of the
seeded cells immediately after implantation,
but subsequent imaging revealed a rapid re-
turn to control levels within 2 hours. The re-
turn to baseline correlated with the loss of
USPIO-labeled cells from the scaffolds as
verified with Prussian blue staining for the
presence of iron oxide-labeled cells. These
data  support  the  theory  of  rapid  loss  of
seeded cells from the TEVGs post-implan-
tation and argues against their role as direct
cellular precursors in the process of neoves-
sel formation [48].
Extracellular Matrix
In addition to the cellular composition
of the neovessel, the characteristics of the
extracellular matrix (ECM) play a critical
role in the determination of the vessel’s bio-
mechanical properties and overall structural
integrity. Deviations from the normal phys-
iological processes of ECM deposition and
remodeling can lead to alterations in the bio-
mechanical properties of the graft, resulting
in complications such as aneurismal dilata-
tion and stenosis. The primary components
of the ECM include collagen, elastin, and
GAG  [39].  Zinc-dependent  enzymes  re-
ferred  to  as  matrix  metalloproteinases
(MMP) also have been shown to be inti-
mately  involved  in  the  process  of  ECM
degradation and remodeling [49]. Using a
C57BL/6 murine model, the quantitative and
qualitative  characteristics  of  these  ECM
components  were  assessed  in  implanted
TEVGs over a 4-week period. Results indi-
cated a trend of early deposition of Type I
and Type III collagen in the neovessel, peak-
ing at 2 weeks. Gene expression levels of
both Type I and Type III collagen were sig-
nificantly higher in the TEVG versus native
IVC at that time point, but there was no sta-
tistical difference by 4 weeks. Type IV col-
lagen was expressed at a lower level in the
graft when compared to native IVC at early
time points but approximated that of vena
cava by 4 weeks. Similarly, analysis of the
total collagen content of the neovessel re-
vealed no difference between the implanted
graft and normal vena cava by the 4-week
time point [50].
Additional experiments revealed that
gene expression levels of elastin increased
within the TEVGs over the course of the ex-
periment, and overall production of GAG
was also significantly greater when com-
pared to earlier time points. Gene expression
studies on the metalloproteinases MMP-9
and MMP-2 revealed high early expression
of MMP-9 followed by a gradual decline,
while MMP-2 expression increased steadily
over time [50]. These patterns are consistent
with previously described models of vascu-
lar injury [51,52]. The presumed roles of
MMP-9 and MMP-2 include induction of an
early inflammatory foreign body reaction
coupled with ECM degradation and remod-
eling, thereby allowing the vascular graft to
adapt to the specific biomechanical envi-
ronment in which it is implanted. These in-
vestigations  provide  some  of  the  first
qualitative and quantitative data clarifying
the sequence of ECM deposition and re-
modeling in TEVGs. These processes play
a critical role in neovessel formation and
may be implicated in many of the complica-
tions arising from deficiencies in the struc-
tural  integrity  of  the  implanted  conduit.
Further work is needed in order to more
fully characterize these mechanisms so that
an improved vascular graft can be designed.
235 Dean et al.: Translation of vascular tissue engineering to pediatric CHDfuTurE DirECTionS
As TEVGs reach clinical fruition, fur-
ther investigation will be necessary to ensure
the long-term success and efficacy of this
technology. The pilot clinical trial conducted
in Japan is promising in finding growth po-
tential, but also challenging in that it points
to areas in need of improvement, namely
prevention of long-term graft stenosis. The
future of TEVG development will lie in both
clinical  and  laboratory  investigation. An
FDA-approved  clinical  trial  is  currently
under way at the Yale School of Medicine to
establish a benchmark for evaluating the
safety of tissue-engineered vascular grafts
for use in the surgical management of pa-
tients born with single ventricle anomalies.
This clinical trial and additional investiga-
tions on the mechanisms of neotissue for-
mation and stenosis will be instrumental in
improving outcomes in patients with CHD
[53,54]. At the same time, the recent devel-
opment of a mouse model and subsequent
laboratory work has pointed toward the me-
diators of neotissue formation and mecha-
nisms of controlling graft stenosis. Second
generation TEVGs will benefit from the un-
folding  understanding  of  how  these  cy-
tokines  dictate  neotissue  formation.
Ultimately, cytokine-eluting TEVGs may re-
place current technology and eliminate the
need for seeding altogether. Equally impor-
tant, current investigations into the develop-
ment and structuring of extracellular matrix
will improve upon scaffold design and open
the door for novel methods of preventing
stenosis.
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